For the quarter ending 2025-09-30, SGMT made $15,801K in revenue. -$12,867K in net income. Net profit margin of -81.43%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | |
|---|---|---|---|---|
| Research and development expenses | 9,730 | 7,248 | 12,653 | |
| General and administrative expenses | 4,604 | 4,677 | 4,249 | |
| Total operating expenses | 14,334 | 11,925 | 16,902 | |
| Loss from operations | -14,334 | -11,925 | -16,902 | |
| Interest income and other, net | 1,426 | 1,539 | 2,283 | |
| Total other income | 1,426 | 1,539 | 2,283 | |
| Net loss | -12,908 | -10,386 | -14,619 | |
| Net unrealized gain (loss) on marketable securities | 41 | -45 | 464 | |
| Total comprehensive loss | -12,867 | -10,431 | -14,155 | |
| Earnings per share, basic | -0.4 | -0.32 | -0.45 | |
| Earnings per share, diluted | -0.4 | -0.32 | -0.45 | |
| Weighted average number of shares outstanding, basic | 32,464,893 | 32,195,366 | 32,143,336 | |
| Weighted average number of shares outstanding, diluted | 32,464,893 | 32,195,366 | 32,143,336 | |
Sagimet Biosciences Inc. (SGMT)
Sagimet Biosciences Inc. (SGMT)